2-Isopropyl-5-nitro-benzimidazol | 16405-84-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 2-Isopropyl-5-nitro-benzimidazol
• 英文别名: 6-nitro-2-propan-2-yl-1H-benzimidazole
• CAS: 16405-84-8
• 化学式: C₁₀H₁₁N₃O₂
• mdl: MFCD01789856
• 分子量: 205.216
• InChiKey: HPTQXZVPWMFRBA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  74.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-Isopropyl-5-nitro-benzimidazol 在 palladium 10% on activated carbon 、 氢气 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 22.08h， 生成 2-hydroxy-5-(N-(2-isopropyl-1H-benzo[d]imidazol-6-yl)sulfamoyl)benzamide
  参考文献：
  名称：

  [EN] 5-SULFAMOYL-2-HYDROXYBENZAMIDE DERIVATIVES
  [FR] DÉRIVÉS DE 5-SULFAMOYL-2-HYDROXYBENZAMIDE

  摘要：

  本发明涉及取代水杨酰胺衍生物。具体而言，本发明涉及根据公式(I)的化合物：其中R、R1和R2如本文所述，或其药用可接受的盐。本发明的化合物是CD73的抑制剂，可用于治疗癌症、前癌症综合症以及与CD73抑制相关的疾病，例如艾滋病、治疗HIV、自身免疫疾病、感染、动脉粥样硬化和缺血再灌注损伤。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明还进一步涉及使用本发明化合物或包含本发明化合物的药物组合物来抑制CD73活性和治疗与之相关的疾病的方法。

  公开号：

  WO2017153952A1
• 作为产物：
  描述：

  4-硝基邻苯二胺 、 异丁酸 反应 16.0h， 以3.3 g的产率得到2-Isopropyl-5-nitro-benzimidazol
  参考文献：
  名称：

  [EN] 5-SULFAMOYL-2-HYDROXYBENZAMIDE DERIVATIVES
  [FR] DÉRIVÉS DE 5-SULFAMOYL-2-HYDROXYBENZAMIDE

  摘要：

  本发明涉及取代水杨酰胺衍生物。具体而言，本发明涉及根据公式(I)的化合物：其中R、R1和R2如本文所述，或其药用可接受的盐。本发明的化合物是CD73的抑制剂，可用于治疗癌症、前癌症综合症以及与CD73抑制相关的疾病，例如艾滋病、治疗HIV、自身免疫疾病、感染、动脉粥样硬化和缺血再灌注损伤。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明还进一步涉及使用本发明化合物或包含本发明化合物的药物组合物来抑制CD73活性和治疗与之相关的疾病的方法。

  公开号：

  WO2017153952A1

文献信息

• Novel benzimidazole derivatives
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US20030181730A1

  公开（公告）日：2003-09-25

  This invention provides compounds having the structure: 1 wherein each of R 1 , R 2 , R 3 and R 9 is independently H; straight chain or branched, substituted or unsubstituted C 1 -C 7 alkyl, C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl or cycloalkenyl; acyl, phenyl, substituted phenyl, or heteroaryl; wherein each dashed line represents a single bond or a double bond with the proviso that if R 1 is present, R 3 is absent and there is a double bond between N at position 3 and C at position 2 and a single bond between C at position 2 and N at position 1 and if R 3 is present, R 1 is absent and there is a double bond between N at position 1 and C at position 2 and a single bond between C at position 2 and N at position 3; wherein each of R 4 , R 5 and R 6 is independently H, F, Cl, Br, I; straight chain or branched, substituted or unsubstituted C 1 -C 7 alkyl, C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl or cycloalkenyl; phenyl, substituted phenyl, heteroaryl, —OH, —OR 7 , —CN, —COR 7 , —CO 2 R 7 , —CON(R 7 ) 2 , —OCOR 7 , —SR 7 , —N(R 7 ) 2 , —NR 7 COR 7 , —(CH 2 ) n OR 7 , —(CH 2 ) n N(R 7 ) 2 , —(CH 2 ) n NR 7 COR 7 , wherein n is an integer from 1 to 4; and wherein each of R 7 and R 8 is independently H; straight chain or branched, substituted or unsubstituted C 1 -C 7 alkyl, C 2 -C 7 alkenyl or alkynyl; phenyl or substituted phenyl. These compounds are selective for cloned human alpha 2 receptors and are useful as analgesic, sedative or anaesthetic agents.

  本发明提供具有结构的化合物：1其中R1，R2，R3和R9中的每一个都是独立的H; 直链或支链，取代或未取代的C1-C7烷基，C2-C7烯基或炔基; C3-C7环烷基或环烯基; 酰基，苯基，取代苯基或杂环基; 其中每个虚线代表单键或双键，前提是如果R1存在，则R3不存在，并且在位置3处的N和位置2处的C之间有双键，在位置2处的C和位置1处的N之间有单键，如果R3存在，则R1不存在，并且在位置1处的N和位置2处的C之间有双键，在位置2处的C和位置3处的N之间有单键; 其中R4，R5和R6中的每一个都是独立的H，F，Cl，Br，I; 直链或支链，取代或未取代的C1-C7烷基，C2-C7烯基或炔基; C3-C7环烷基或环烯基; 苯基，取代苯基，杂环基，—OH，—OR7，—CN，—COR7，—CO2R7，—CON(R7)2，—OCOR7，—SR7，—N(R7)2，—NR7COR7，—(CH2)nOR7，—( )nN(R7)2，—( )nNR7COR7，其中n是1到4的整数; 其中R7和R8中的每一个都是独立的H; 直链或支链，取代或未取代的C1-C7烷基，C2-C7烯基或炔基; 苯基或取代苯基。 这些化合物对克隆的人类α2受体具有选择性，并可用作镇痛，镇静或麻醉剂。
• Benzimidazole derivatives
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US06403626B1

  公开（公告）日：2002-06-11

  This invention provides compounds having the structure: wherein each of R1, R2, R3 and R9 is independently H; straight chain or branched, substituted or unsubstituted C1-C7 alkyl, C2-C7 alkenyl or alkynyl; C3-C7 cycloalkyl or cycloalkenyl; acyl, phenyl, substituted phenyl, or heteroaryl; wherein each dashed line represents a single bond or a double bond with the proviso that if R1 is present, R3 is absent and there is a double bond between N at position 3 and C at position 2 and a single bond between C at position 2 and N at position 1 and if R3 is present, R1 is absent and there is a double bond between N at position 1 and C at position 2 and a single bond between C at position 2 and N at position 3; wherein each of R4, R5 and R6 is independently H, F, Cl, Br, I; straight chain or branched, substituted or unsubstituted C1-C7 alkyl, C2-C7 alkenyl or alkynyl; C3-C7 cycloalkyl or cycloalkenyl; phenyl, substituted phenyl, heteroaryl, —OH, —OR7, —CN, —COR7, —CO2R7, —CON(R7)2, —OCOR7, —SR7, —N(R7)2, —NR7COR7, —(CH2)nOR7, —(CH2)nN(R7)2, —(CH2)nNR7COR7, wherein n is an integer from 1 to 4; and wherein each of R7 and R8 is independently H; straight chain or branched, substituted or unsubstituted C1-C7 alkyl, C2-C7 alkenyl or alkynyl; phenyl or substituted phenyl. These compounds are selective for cloned human alpha 2 receptors and are useful as analgesic, sedative or anaesthetic agents.

  本发明提供了具有以下结构的化合物：其中R1、R2、R3和R9中的每一个独立地是H；直链或支链，取代或未取代的C1-C7烷基，C2-C7烯基或炔基；C3-C7环烷基或环烯基；酰基，苯基，取代苯基或杂环基；其中每个虚线表示单键或双键，但如果R1存在，则R3不存在，并且在位置3的N和位置2的C之间存在双键，在位置2的C和位置1的N之间存在单键，如果R3存在，则R1不存在，并且在位置1的N和位置2的C之间存在双键，在位置2的C和位置3的N之间存在单键；其中R4、R5和R6中的每一个独立地是H、F、Cl、Br、I；直链或支链，取代或未取代的C1-C7烷基，C2-C7烯基或炔基；C3-C7环烷基或环烯基；苯基，取代苯基，杂环基，—OH，—OR7，—CN，—COR7，—CO2R7，—CON（R7）2，—OCOR7，—SR7，—N（R7）2，—NR7COR7，—（CH2）nOR7，—（ ）nN（R7）2，—（ ）nNR7COR7，其中n是1到4的整数；其中R7和R8中的每一个独立地是H；直链或支链，取代或未取代的C1-C7烷基，C2-C7烯基或炔基；苯基或取代苯基。这些化合物选择性地作用于克隆的人类α2受体，并且可用作镇痛、镇静或麻醉剂。
• Developing agent for silver halide photographic material, developing solution composition and method for developing silver halide photographic material
  申请人：FUJI PHOTO FILM CO., LTD.

  公开号：EP0710880A1

  公开（公告）日：1996-05-08

  A silver halide photographic material is processed with a developing solution containing at least one kind of developing agent represented by the following general formula (A): wherein R₁ and R₂ may be the same or different, and each represents a hydrogen atom or a substituent group, with the proviso that R₁ and R₂ are not methyl groups at the same time nor a combination of a hydrogen atom and a methyl group, thereby providing a novel method for forming an image by use of the developing solution not using a dihydroxybenzene compound as the developing agent, and more particularly a superhigh contrast negative image by use of the photographic material containing a hydrazine compound.

  卤化银感光材料用含有至少一种由以下通式（A）表示的显影剂的显影液冲洗： 其中 R₁ 和 R₂ 可以相同或不同，并且各自代表氢原子或取代基，但 R₁ 和 R₂ 不能同时为甲基，也不能是氢原子和甲基的组合、从而提供了一种通过使用不使用二羟基苯化合物作为显影剂的显影液来形成图像的新方法，尤其是通过使用含有肼化合物的感光材料来形成超高对比度的底片图像。
• Fine polymer particles having heterogeneous phase structure, silver halide photographic light- sensitive material containing the fine polymer particles and image-forming method
  申请人：FUJI PHOTO FILM CO., LTD.

  公开号：EP0716338A2

  公开（公告）日：1996-06-12

  Latex polymer of fine particles having a heterogeneous phase structure which comprises a core of a polymer having repeating units derived from a conjugated diene monomer and a shell of a polymer having repeating units derived from at least one ethylenically unsaturated monomer carrying an active methylene group; a silver halide photographic light-sensitive material comprises a core/shell latex polymer whose shell consists of a polymer having repeating units of an ethylenically unsaturated monomer represented by the formula: CH₂=C(R¹)-L-X (wherein R¹ represents H, alkyl or halogen, L represents a single bond or a bivalent coupling group, X represents an active methylene group, provided that L is bonded to X in the form of alkylene; and a method for forming images on a silver halide light-sensitive material which comprises exposing the material which comprises at least one light-sensitive silver halide emulsion layer and at least one hydrophilic colloidal layer either of which comprises a latex polymer having active methylene groups and developing the exposed material with a developer which comprises a dihydroxybenzene developing agent and an auxiliary developing agent showing superadditivity, the pH increase observed when adding 0.1mole/ℓ developer of NaOH to the developer ≦ 0.25; 9.5 ≦ initial pH of the developer ≦ 11.0; the amount of the developer supplemented≦ 225 ml/m².

  具有异相结构的细颗粒乳胶聚合物，其核由具有来自共轭二烯单体的重复单元的聚合物组成，壳由具有来自至少一种带有活性亚甲基的乙烯不饱和单体的重复单元的聚合物组成；卤化银感光材料由核/壳乳胶聚合物组成，其壳由具有由式表示的乙烯不饱和单体的重复单元的聚合物组成：CH₂=C(R¹)-L-X(其中R¹代表H、烷基或卤素，L代表单键或二价偶联基团，X代表活性亚甲基，条件是L以亚烷基的形式与X键合)；以及一种在卤化银感光材料上形成图像的方法，该方法包括曝光该材料，该材料包括至少一个感光卤化银乳剂层和至少一个亲水胶体层，其中任一亲水胶体层包括具有活性亚甲基的乳胶聚合物，并用显影剂显影曝光的材料，该显影剂包括二羟基苯显影剂和显示超加成性的辅助显影剂，当加入 0.1mole/ℓ 显影剂的 NaOH 时观察到的 pH 值增加 ≦ 0.25；9.5 ≦ 显影剂的初始 pH ≦ 11.0；补充的显影剂量 ≦ 225 ml/m²。
• Silver halide photographic material
  申请人：FUJI PHOTO FILM CO., LTD.

  公开号：EP0736798A1

  公开（公告）日：1996-10-09

  A silver halide photographic material comprising at least one of hydrazide compounds represented by formula (1), (2) or (3):         X1-(R3)m3-(L2-R2)m2-L1-A1-NHNH-CO-R1     (1)         X21-(R23)m23-(L22-R22)m22-L21-Ar-NHNH-CO-R21     (2) The substituents in formulae (1), (2) and (3) are defined in the specification.

  一种卤化银感光材料，包含至少一种由式 (1)、(2) 或 (3) 所代表的酰肼化合物： X1-(R3)m3-(L2-R2)m2-L1-A1-NHNH-CO-R1 (1) X21-(R23)m23-(L22-R22)m22-L21-Ar-NHNH-CO-R21 (2) 式(1)、(2)和(3)中的取代基在说明书中定义。